journal article·2017-02-17Open access

Oxaliplatin immunohybrid nanoparticles in vitro synergistic suppression evaluation in treatment of colorectal cancer

Shashank Tummala, K. Gowthamarajan, M. N. Satish Kumar

Abstract

In the present study, we have investigated the enhanced synergistic and apoptotic activity of immunohybrid nanoparticles encapsulating oxaliplatin and covalently conjugated with TRAIL (Apo-2L/CD-253). Time-dependent cytotoxicity activity of nanoparticles was determined by MTT assay in HT-29 cells. Nuclear morphological changes and assessment of apoptotic ratio was analyzed by DAPI (4'6-diamidino-2-phenylindole) staining and annexin-propidium iodide (PI) assay. Cell-cycle analysis of oxaliplatin in HT-29 cell was analyzed by flow cytometry at 72 h. Furthermore, molecular mechanisms related to oxaliplatin-induced anticancer activity was explored by western blot analysis. Our study revealed appreciable time-dependent cytotoxicity, apoptotic, and synergistic activity of oxaliplatin immunohybrid nanoparticles.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Drug Transport and Resistance Mechanisms · Metal complexes synthesis and properties

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutics, J. S. S. College of Pharmacy (off-Campus), J. S. S University, Mysore, Karnataka, India;

Department of Pharmacology, J. S. S. College of Pharmacy (off-Campus), J. S. S University, Mysore, Karnataka, India

References (30)

Show source-provided references
1. 10.1021/mp800051m10.1021/mp800051m ↗
2. 10.1038/nrc96810.1038/nrc968 ↗
3. 10.1016/j.jconrel.2011.09.09810.1016/j.jconrel.2011.09.098 ↗
4. 10.1016/j.addr.2008.08.00510.1016/j.addr.2008.08.005 ↗
5. 10.1053/sonc.2002.3552410.1053/sonc.2002.35524 ↗
6. 10.1016/j.colsurfb.2014.01.00710.1016/j.colsurfb.2014.01.007 ↗
7. 10.1016/j.jconrel.2010.02.02610.1016/j.jconrel.2010.02.026 ↗
8. 10.1093/jjco/hyi13010.1093/jjco/hyi130 ↗
9. 10.3109/21691401.2015.100850310.3109/21691401.2015.1008503 ↗
10. Hashimoto Y · Liposome Technol · 1984 · 3 · 41
11. 10.1016/0009-3084(86)90078-210.1016/0009-3084(86)90078-2 ↗
12. 10.1016/j.ejphar.2009.06.06610.1016/j.ejphar.2009.06.066 ↗
13. 10.3109/21691401.2014.99883010.3109/21691401.2014.998830 ↗
14. 10.3109/21691401.2014.90982210.3109/21691401.2014.909822 ↗
15. 10.1016/j.bbamcr.2003.08.00910.1016/j.bbamcr.2003.08.009 ↗
16. Krishnaiah Y · 2001 · 89
17. Leserman LD · Liposome Technol · 1984 · 3 · 29
18. 10.1038/sj.cr.729028110.1038/sj.cr.7290281 ↗
19. 10.1016/j.semcancer.2005.06.00510.1016/j.semcancer.2005.06.005 ↗
20. Nair KL · Int J Nanomed · 2011 · 6 · 1685
21. 10.1038/nnano.2007.38710.1038/nnano.2007.387 ↗
22. 10.1016/S0167-4781(01)00204-410.1016/S0167-4781(01)00204-4 ↗
23. Torchilin VP. · Liposome Technol · 1984 · 3 · 75
24. 10.3109/10717544.2015.108440010.3109/10717544.2015.1084400 ↗
25. Tummala S · Indo Amer J Pharm Res · 2014 · 4 · 3579
26. 10.1016/j.jsps.2014.11.01010.1016/j.jsps.2014.11.010 ↗
27. 10.3109/21691401.2015.111122610.3109/21691401.2015.1111226 ↗
28. 10.1038/551710.1038/5517 ↗
29. 10.1038/nrd274210.1038/nrd2742 ↗
30. 10.3748/wjg.v18.i7.64610.3748/wjg.v18.i7.646 ↗